NCT06240143View on ClinicalTrials.gov

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 8, 2024

Primary Completion Date

July 31, 2029

Study Completion Date

March 31, 2034

Conditions
Melanoma
Interventions
DRUG

Ipilimumab

intradermal

DRUG

Nivolumab

intradermal

DRUG

Nivolumab

intravenous

Trial Locations (6)

Unknown

NOT_YET_RECRUITING

Amsterdam University Medical Center, Amsterdam

RECRUITING

Antoni van Leeuwenhoek Hospital, Amsterdam

RECRUITING

University Medical Center Groningen, Groningen

NOT_YET_RECRUITING

Leiden University Medical Center, Leiden

NOT_YET_RECRUITING

Erasmus University Medical Center, Rotterdam

NOT_YET_RECRUITING

University Medical Center Utrecht, Utrecht

All Listed Sponsors
lead

The Netherlands Cancer Institute

OTHER